A1
L-citrulline
- Product declaration
- L-Citrulline: 6 g
- Selected studied range
- 3000 to 9000 mg
- Protocol and duration
- per day, in the studies NIH ODS summarizes
- Studied context
- Studied as a nitric-oxide pathway precursor (converted to arginine via the urea cycle) for aerobic exercise performance measures such as oxygen-uptake (VO2) kinetics, blood lactate, and rate of perceived exertion, and for acute resistance-exercise performance and muscle oxygenation. NIH ODS describes evidence for enhancing performance as limited, with few studies and conflicting results.
- Limitations
- A 2022 systematic review/meta-analysis found no significant benefit for endurance-performance outcomes specifically. A single 8 g acute dose did not enhance isometric force production, muscle endurance, or muscle-oxygenation parameters in one resistance-exercise study. NIH ODS characterizes overall performance-enhancement evidence as limited.
Selected evidence: NIH ODS, Dietary Supplements for Exercise and Athletic Performance · Open source
A2
Creatine monohydrate
- Product declaration
- Creatine Monohydrate: 5 g
- Selected studied range
- 3000 to 5000 mg
- Protocol and duration
- per day maintenance, after an optional loading phase
- Studied context
- The ISSN 2017 position stand calls creatine monohydrate "the most effective ergogenic nutritional supplement currently available to athletes" for increasing high-intensity/intermittent exercise capacity and lean body mass during training. It also describes research into post-exercise recovery, injury prevention, thermoregulation, rehabilitation, concussion/spinal-cord neuroprotection, and use in clinical populations (aging-related sarcopenia, neurodegenerative disease, type 2 diabetes glycemic control), while noting creatine is "of little value" for pure endurance sports (per NIH ODS).
- Limitations
- ISSN 2017 states it is not yet established whether other creatine forms (e.g., creatine nitrate, or precursors like guanidinoacetic acid/GAA) produce greater muscle or brain creatine uptake than monohydrate. This is described as an active area of research, not a settled finding.
Selected evidence: ISSN position stand on creatine safety and efficacy, 2017 · Open source
A2
Beta-alanine
- Product declaration
- Beta-Alanine: 3.2 g
- Selected studied range
- 4000 to 6000 mg
- Protocol and duration
- per day in divided doses, for at least 2 to 4 weeks, not as a single pre-workout dose
- Studied context
- Studied for high-intensity exercise capacity in the 60-240 second range via elevation of muscle carnosine, which acts as an intracellular pH buffer against acidosis. ISSN 2015 position stand: greatest performance benefits in "open end-point" tasks/time trials lasting 1-4 minutes; some benefit noted in aerobic exercise up to roughly 25 minutes; attenuation of neuromuscular fatigue, particularly noted in older adults.
- Limitations
- Strength/resistance-training outcomes remain mixed; training volume may increase without a clear strength gain. Tasks under 60 seconds do not show benefit. Endurance benefit beyond about 25 minutes is not established. Long-term safety data beyond roughly a year, and effects in special/tactical populations, are flagged as needing more research.
Selected evidence: ISSN position stand on beta-alanine, 2015 · Open source
A1
Betaine anhydrous
- Product declaration
- Betaine Anhydrous: 2 g
- Selected studied range
- 2000 to 5000 mg
- Protocol and duration
- per day, studied for up to 15 days
- Studied context
- NIH ODS describes betaine as studied for strength- and power-based performance in bodybuilders and cyclists, with "potential but modest" improvements from a limited set of small, sometimes conflicting studies. A 2024/2025 systematic review focused specifically on endurance performance (VO2max, time-to-exhaustion, time-to-completion, power output).
- Limitations
- The endurance systematic review explicitly states "limited and inconclusive evidence regarding the definitive ergogenic effect of betaine supplementation on endurance exercise performance". Only 2 of 5 reviewed studies showed a significant improvement, and the authors call for "additional, more rigorous research."
Selected evidence: NIH ODS, Dietary Supplements for Exercise and Athletic Performance · Open source
A2
Agmatine sulfate
- Product declaration
- Agmatine Sulfate: 1.5 g
- Selected studied range
- No dose range selected
- Protocol and duration
- Not recorded in the selected comparison
- Studied context
- Human data is comparatively sparse. A randomized double-blind placebo-controlled trial studied oral agmatine sulfate (1,335-3,560 mg/day for up to 3 weeks) for lumbar disc-associated radiculopathy (a clinical/pain context, not sports performance). A 2019 Scientific Reports paper examined safety and neurochemical profiles of acute and sub-chronic oral agmatine sulfate treatment.
- Limitations
- Sports-performance-specific human efficacy data for agmatine sulfate (e.g., a dedicated ISSN position stand) was not located in this research pass. Evidence located centers on safety/tolerability and non-sports clinical contexts rather than an authoritative performance-outcome verdict. Long-term safety in larger populations remains an open gap per the safety literature reviewed.
Selected evidence: Safety and neurochemical profiles of oral agmatine sulfate, 2019 · Open source
A2
L-tyrosine
- Product declaration
- L-Tyrosine: 1.5 g
- Selected studied range
- 2000 to 2000 mg
- Protocol and duration
- per day for five days, in the cadet study
- Studied context
- Studied as the dietary precursor to norepinephrine for mitigating cognitive performance decrements under acute stress. A 2015 Military Medicine evidence review (rapid evidence assessment, 14 trials: 10 RCTs + 4 controlled clinical trials) issued a "weak recommendation" in favor of tyrosine for cognitive stress specifically, stating "all studies showed a positive effect" on that outcome. A widely cited primary study (Deijen et al. 1999, Brain Research Bulletin) gave cadets 2 g tyrosine daily for five days during a combat training course and found better memory and tracking-task performance, plus lower systolic blood pressure, versus a carbohydrate control.
- Limitations
- The 2015 Military Medicine review states explicitly that "no recommendation could be made" for tyrosine's effect on physical performance under stressful physical conditions, and concludes "available evidence is insufficient to make confident recommendations on the effectiveness of tyrosine for mitigating stress effects on physical/cognitive performance" overall, despite the positive signal on cognition. A separate heat-stress study found tyrosine ingestion did not influence cognitive function or physical performance during exercise heat stress despite raised serum tyrosine. NIH ODS's exercise/athletic-performance fact sheet does not cover tyrosine at all.
Selected evidence: Deijen et al., Brain Research Bulletin, 1999
A1
Choline bitartrate
- Product declaration
- VitaCholine® Choline Bitartrate: 400 mg
- Selected studied range
- 425 to 550 mg
- Protocol and duration
- Adequate Intake for adults, a nutrient reference and not an ergogenic dose
- Studied context
- NIH ODS's Choline Health Professional fact sheet establishes choline's core physiological roles: synthesis of phosphatidylcholine and sphingomyelin for cell-membrane structure, acetylcholine (a neurotransmitter for memory, mood, and muscle control) production, methyl-group donation, gene-expression modulation, and brain development. Choline bitartrate is named as one of three supplement forms (with phosphatidylcholine and lecithin).
- Limitations
- NIH ODS states explicitly: "No studies have compared the relative bioavailability of choline from these different forms". Meaning choline bitartrate's absorption/efficacy relative to phosphatidylcholine, lecithin, or non-bitartrate forms (like alpha-GPC) is not established by NIH's own review.
Selected evidence: NIH ODS, Choline fact sheet · Open source
A1
Theobromine
- Product declaration
- Theobromine: 100 mg
- Selected studied range
- No dose range selected
- Protocol and duration
- Not recorded in the selected comparison
- Studied context
- EFSA's Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF), in its 2017 opinion on xanthine alkaloids from the flavoring priority list, treats theobromine as a major metabolite of caffeine. Roughly 11% of an ingested caffeine dose converts systemically to theobromine. And states that because "only limited toxicity data in humans are available" for theobromine directly, its safety assessment leans on the extensive caffeine safety literature (EFSA's 2015 caffeine opinion) rather than an independent human-efficacy dataset for theobromine as a standalone ergogenic ingredient.
- Limitations
- No sports-performance-specific position stand or ISSN evaluation of theobromine as a standalone ergogenic ingredient was located in this research pass. EFSA's own framing acknowledges limited independent human toxicity data on theobromine itself.
Selected evidence: EFSA Flavouring Group Evaluation 49 Revision 1, 2017 · Open source
